aTYR PHARMA INC Shareholders' Equity
aTYR PHARMA INC (ATYR) had Shareholders' Equity of $48.79 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity Attributable to Parent $48.79M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $57.93M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $67.48M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $80.23M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $48.79M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $57.93M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $67.48M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $80.23M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $74.84M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $75.05M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $70.02M 10-K · filed 2026-03-05 |
| 2024-09-30 | $65.33M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $81.61M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $84.47M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $90.66M 10-K · filed 2025-03-13 |
| 2023-09-30 | $98.39M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $106.24M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $109.88M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $71.46M 10-K · filed 2024-03-14 |
| 2022-09-30 | $77.18M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $86.64M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $98.55M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $109.30M 10-K · filed 2023-03-14 |
| 2021-09-30 | $117.61M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $40.98M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $49.70M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $31.65M 10-K · filed 2022-03-15 |
| 2020-09-30 | $32.16M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $36.10M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $42.13M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $21.19M 10-K · filed 2021-03-24 |
| 2019-09-30 | $26.74M 10-Q · filed 2020-11-13 |
| 2019-06-30 | $30.23M 10-Q · filed 2020-11-13 |
| 2019-03-31 | $29.48M 10-Q · filed 2020-11-13 |
| 2018-12-31 | $33.65M 10-K · filed 2021-03-24 |
| 2018-09-30 | $38.99M 10-Q · filed 2019-11-14 |
| 2018-06-30 | $45.38M 10-Q · filed 2019-11-14 |
| 2018-03-31 | $54.50M 10-Q · filed 2019-11-14 |
| 2017-12-31 | $64.25M 10-K · filed 2021-03-24 |
| 2017-09-30 | $72.29M 10-Q · filed 2017-11-14 |
| 2017-06-30 | $40.03M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $50.71M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $62.80M 10-K · filed 2020-03-26 |
| 2016-09-30 | $73.99M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $86.57M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $100.43M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $115.05M 10-K · filed 2019-03-26 |
| 2015-09-30 | $129.16M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $139.34M 10-Q · filed 2015-08-12 |
| 2015-03-31 | -$98.01M 10-Q · filed 2015-06-18 |
| 2014-12-31 | -$91.01M 10-K · filed 2018-03-20 |
| 2013-12-31 | -$66.08M 10-K · filed 2017-03-16 |
| 2012-12-31 | -$64.55M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |